Note 6 – Stockholders’ Equity

During the six months ended June 30, 2019 and 2019, there were no sales of our preferred stock. At June 30, 2019 and December 31, 2018, there were no issued or outstanding shares of preferred stock. During the six months ended June 30, 2019, PoC Capital (our clinical trial funding commitment investor), made payments directly to our CRO totaling $395,927 for amounts being currently invoiced, thereby reducing the subscription receivable to $1,404,073. Subsequent to June 30, 2019, PoC Capital has made additional payments totaling $193,299 directly to our CRO. We paid $239,129, $158,000 of which is included in Prepaid and Other on our balance sheet, directly to our CRO at the beginning of our trial that we expect PoC Capital to repay us for. We will continue to reduce the subscription receivable in the period PoC Capital makes payment to our CRO or us.